Guardant Health, Inc.
HealthcareNASDAQ:GH · NASDAQ Global Select
+$0.72 today
Vol 1.45M · Avg 2.19M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$416.3M +4.6% | -$436.4M +9.0% | -$479.4M +26.8% | -$654.6M -70.1% | -$384.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $39.7M -6.3% | $42.4M -1.2% | $42.9M +19.2% | $36.0M +61.5% | $22.3M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $166.2M +18.4% | $140.4M +54.7% | $90.8M -4.1% | $94.7M -37.5% | $151.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $9.8M +116.1% | -$60.9M -213.0% | $53.8M -12.5% | $61.6M +252.1% | -$40.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$28.2M -31.7% | -$21.4M -355.3% | $8.4M +2134.1% | $375.0K +100.8% | -$44.4M | $592.6M | $1.3B | $626.2M |
| Inventory | -$14.8M -61.9% | -$9.1M +11.7% | -$10.3M +50.5% | -$20.9M -163.0% | -$8.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $52.7M +1970.5% | -$2.8M | $0 -100.0% | $60.3M +598.4% | $8.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $0 +100.0% | -$27.5M -149.3% | $55.8M +156.2% | $21.8M +580.0% | $3.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $15.8M -78.8% | $74.6M +326.0% | -$33.0M -121.6% | $152.9M +259.8% | $42.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$184.8M +23.0% | -$239.9M +26.2% | -$325.0M -5.0% | -$309.5M -48.1% | -$209.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$48.3M -37.7% | -$35.1M -71.3% | -$20.5M +73.6% | -$77.5M -3.2% | -$75.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$59.0M | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$827.2M -162.8% | -$314.8M +50.5% | -$635.5M -93.9% | -$327.7M +65.1% | -$940.2M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $307.3M +246.9% | $88.6M -94.1% | $1.5B +169.6% | $555.0M -41.7% | $952.1M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$627.2M -140.0% | -$261.3M -131.1% | $840.3M +460.9% | $149.8M +337.2% | -$63.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 +100.0% | -$71.0K +51.4% | -$146.0K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $87.9M +492.2% | $14.8M -97.0% | $493.1M | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $13.6M | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $569.7M +3697.8% | -$15.8M -0.6% | -$15.7M +91.7% | -$189.0M -183.5% | -$66.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $671.1M +67482.8% | -$996.0K -100.2% | $477.4M +352.5% | -$189.1M -183.0% | -$66.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $491.0K +127.7% | -$1.8M -94.3% | -$911.0K +43.1% | -$1.6M +5.5% | -$1.7M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$140.3M +72.2% | -$503.9M -150.8% | $991.7M +383.1% | -$350.3M -2.8% | -$340.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$233.1M +15.2% | -$274.9M +20.4% | -$345.5M +10.7% | -$386.9M -36.2% | -$284.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Viatris Inc.
NASDAQ:VTRS
$19.19B
Solventum Corporation
NYSE:SOLV
$13.66B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Revvity, Inc.
NYSE:RVTY
$11.12B
Encompass Health Corporation
NYSE:EHC
$10.07B
Qiagen N.V.
NYSE:QGEN
$7.64B
SEC Filings
Recent regulatory filings
No filings found.
Does GH generate free cash flow?
Guardant Health, Inc. (GH) generated -$233,066,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does GH produce?
Operating cash flow was -$184,760,000.00, before capital expenditures of $48.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.